Bavarian Nordic has initiated two Phase III clinical trials of its mpox vaccine, Jynneos, in pregnant and breastfeeding women ...

Bavarian Nordic initiates clinical trials of mpox vaccine in infants and pregnant women: Copenhagen, Denmark Saturday, June 28, 2025, 12:00 Hrs [IST] Bavarian Nordic A/S, a global ...

Sale prices for the vouchers – which slash FDA review times for a drug – have increased in the past year as biotech funding ...

The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

Clinical trials of Jynneos have begun or will begin soon in infants and children 2 years old and younger, and in pregnant or ...

Bavarian Nordic produces one of the only vaccines for mpox and its shots are the only ones licensed for the disease in the U.S. and European Union.

Danish biotech firm Bavarian Nordic could ramp up production of its mpox vaccine even before having orders lined up, based on the outcome of talks this week with the World Health Organisation, the ...

Bavarian Nordic Gets $63 Million US Government Order for Small Pox, Mpox Vaccine (Reuters) - Bavarian Nordic has received an order worth $63 million from the U.S. government to produce additional ...

Bavarian Nordic CEO Paul Chaplin told STAT that 2 million doses of Jynneos vaccine could be produced this year, 8 million in 2025, to protect against mpox. Skip to Main Content.

Aug 17 (Reuters) - Danish biotech firm Bavarian Nordic , opens new tab said on Saturday it plans to ramp up production of its mpox vaccine and work with international health organisations to ...

Bavarian Nordic is also sponsoring a trial (NCT06549530) of MVA-BN in children aged 2-11 years, with topline data anticipated in Q3 2025. Jynneos is the only non-replicating mpox vaccine approved ...

First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner ...